Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 713-722 , December 2009

Tyrosine kinase inhibitors and the thyroid

References 

  1. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer. 2009;9:28–39
  2. Weinstein IB, Joe A. Oncogene addiction. Cancer Research. 2008;68:3077–3080
  3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  4. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clinical Practice Oncology. 2008;5:521–530
  5. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clinical Cancer Research. 2008;14:3651–3656
  6. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clinical Cancer Research. 2009;15:2207–2214
  7. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology. 2009;27:2278–2287
  8. Rokosz LL, Beasley JR, Carroll CD, et al. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opinion on Therapeutic Targets. 2008;12:883–903
  9. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Seminars in Surgical Oncology. 1999;16:34–41
  10. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Review of Molecular Diagnostics. 2008;8:83–95
  11. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2001;86:656–658
  12. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129:552–558
  13. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2006;91:3667–3670
  14. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nature Reviews. 2009;6:219–228
  15. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current Opinion in Cell Biology. 2009;21:296–303
  16. Santarpia L, Ye L, Gagel RF. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. Journal of Internal Medicine. 2009;266:99–113
  17. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Molecular Cancer Research. 2008;6:751–759
  18. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. Journal of Clinical Oncology. 2009;27:[abstract]
  19. Schwartz GK, Yazji S, Mendelson DS, et al. A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients with advanced solid tumors. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. October 2008; Geneva.
  20. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research. 2006;66:8715–8721
  21. Coxon A, Bready J, Fiorino M, et al. Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts. Thyroid. 2006;16:920
  22. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 2007;25:2369–2376
  23. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000;92:205–216
  24. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. The New England Journal of Medicine. 2008;359:31–42
  25. Schlumberger M, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of Clinical Oncology 2009; 27: 3794–3801.
  26. Lu J, Claret L, Sutjandra L, et al. Population pharmacokinetic (PK)/pharmacodynamic (PD) modeling and simulations for exposure-tumor response relationships: motesanib in a phase II thyroid cancer (TC) trial. Journal of Clinical Oncology. 2009;27:[abstract e14528]
  27. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research. 2004;64:7099–7109
  28. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. Journal of the National Cancer Institute. 2006;98:326–334
  29. Henderson YC, Ahn SH, Kang Y, et al. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clinical Cancer Research. 2008;14:4908–4914
  30. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426–437
  31. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2006;24:2505–2512
  32. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology. 2009;27:1675–1684
  33. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology. 2008;26:4714–4719
  34. Brose MS, Troxel AB, Redlinger M, et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. Journal of Clinical Oncology. 2009;27:[abstract 6002]
  35. Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Current Opinion in Oncology. 2007;19:18–23
  36. Kober F, Hermann M, Handler A, et al. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. Journal of Clinical Oncology. 2007;25:14065
  37. Lam ET, Ringel MD, Kloos RT, et al. A phase II study of sorafenib in patients with metastatic medullary thyroid carcinoma. 100th Annual Meeting of the American Association of Cancer Researchers April 21, 2009 Denver.
  38. Chintala L, Kurzrock R, Fu S, et al. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). Journal of Clinical Oncology. 2008;26:3593
  39. Nagaiah G, Fu P, Wasman JK, et al. Phase II trial of sorafenib (BAY 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). Journal of Clinical Oncology. 2009;27:[abstract 6058]
  40. Sherman S.I. NCCN practice guidelines for thyroid cancer, version 2009a.; 2009 [updated 2009; cited May 1, 2009]; Available from: www.nccn.org.
  41. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): the M.D. Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology. 2009;27:[abstract 6060]
  42. Waguespack SG, Sherman SI, Williams MD, et al. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009;19:407–412
  43. Dubauskas Z, Kunishige J, Prieto V, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clinical Genitourinary Cancer. 2009;7:20–23
  44. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. The American Journal of Pathology. 2004;165:35–52
  45. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of Clinical Oncology. 2005;23:5474–5483
  46. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology. 2008;26:4708–4713
  47. Bocci G, Man S, Green SK, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Research. 2004;64:6616–6625
  48. Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs. 2007;16:239–249
  49. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research. 2002;62:4645–4655
  50. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research. 2002;62:7284–7290
  51. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23:6056–6063
  52. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Annals of Oncology. 2005;16:1391–1397
  53. Wells SA. Molecular targeted therapeutics in medullary thyroid carcinoma: results of recent clinical trials. Frontiers in Thyroid Cancer: ATA guidelines in clinical practice. Miami: American Thyroid Association, January 23–24, 2009.
  54. Akeno-Stuart N, Croyle M, Knauf JA, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Research. 2007;67:6956–6964
  55. Haddad RI, Krebs AD, Vasselli J, et al. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology. 2008;26:6024
  56. Fox E, Widemann BC, Whitcomb PO, et al. Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma. Journal of Clinical Oncology. 2009;27:[abstract 10014]
  57. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4070–4076
  58. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Annals of Internal Medicine. 2008;148:567
  59. Dawson SJ, Conus NM, Toner GC, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 2008;19:547–552
  60. Cohen EEW, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology. 2008;26:6025
  61. Ravaud A, de la Fouchardière C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. [updated 2008; cited December 15, 2008]; Available from: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view%26amp;confID=55%26amp;abstractID=331442008;
  62. Carr L, Goulart B, Martins R, et al. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC). Journal of Clinical Oncology. 2009;27:[abstract 6056]
  63. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate. Cancer. 2008;112:2500–2508
  64. Bible KC, Smallridge RC, Maples WJ, et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thryoid cancers. Journal of Clinical Oncology. 2009;27:[abstract 3521]
  65. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. 2002;62:5749–5754
  66. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine. 2004;350:2129–2139
  67. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2007;18:317–323
  68. Fury MG, Solit DB, Su YB, et al. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2007;59:467–475
  69. Cui JJ. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opinion on Therapeutic Patents. 2007;17:1035–1045
  70. Mineo R, Costantino A, Frasca F, et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology. 2004;145:4355–4365
  71. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. The American Journal of Surgical Pathology. 2005;29:544–549
  72. Papotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocrine Pathology. 2000;11:19–30
  73. Kurzrock R, Sherman S, Hong D, et al. A Phase 1 Study of XL184, a MET, VEGFR2, and RET Kinase Inhibitor, Administered Orally to Patients (pts) with Advanced Malignancies, Including a Subgroup of Pts with Medullary Thyroid Cancer (MTC) 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008; Geneva. 2008.
  74. Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661–672
  75. Ghori F, Polder KD, Pinter-Brown LC, et al. Thyrotoxicosis following denileukin diftitox therapy in patients with mycosis fungoides. The Journal of Clinical Endocrinology and Metabolism. 2006;
  76. Smith GL, Smith BD, Garden AS, et al. Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study. Head Neck. 2009;
  77. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. The New England Journal of Medicine. 1999;340:1075–1079
  78. Golden WM, Weber KB, Hernandez TL, et al. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. The Journal of Clinical Endocrinology and Metabolism. 2007;92:124–130
  79. Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Annals of Internal Medicine. 2006;145:702–703
  80. de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics. 2005;78:433–438
  81. Pacini F, Sherman SI, Schlumberger M, et al. Exacerbation of postsurgical hypothyroidism during treatment of advanced differentiated (DTC) or medullary (MTC) thyroid carcinoma with AMG 706. Hormone Research. 2007;68(Suppl. 3):29
  82. Dora JM, Leie MA, Netto B, et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. European Journal of Endocrinology. 2008;158:771–772
  83. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine. 2006;145:660–664
  84. Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. European Journal of Endocrinology. 2009;160:331–336
  85. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology. 2008;19:265–268
  86. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351–355
  87. Garfield DH, Wolter P, Schoffski P, et al. Documentation of thyroid function in clinical studies with sunitinib: why does it matter?. [author ] Journal of Clinical Oncology. 2008;26:5131–5132reply pp. 5132–5133
  88. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer. 2008;8:592–603
  89. Ford R, Schwartz L, Dancey J, et al. Lessons learned from independent central review. European Journal of Cancer. 2009;45:268–274
  90. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. Journal of Clinical Oncology. 2009;27:2874–2880
  91. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. Journal of Medicinal Chemistry. 2003;46:1116–1119

PII: S1521-690X(09)00082-7

doi: 10.1016/j.beem.2009.08.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 6 , Pages 713-722 , December 2009

Article Tools